Open AccessThe efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis
Author(s) -
Saijin Cui,
Yaling Zhang,
Lu Liu,
Yan Li,
RongMiao Zhou,
Xi Huang,
Shiru Cao,
Xiangran Huo,
Na Wang
Publication year - 2021
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-20-1357
Subject(s) - osimertinib , medicine , t790m , lung cancer , oncology , cochrane library , meta analysis , adverse effect , population , cancer , epidermal growth factor receptor , gefitinib , erlotinib , environmental health
Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved by the U.S. Food and Drug Administration in treating T790M mutationpositive advanced non-small cell lung cancer (NSCLC). A systematic review and meta-analysis was conducted to assess the efficacy and safety of osimertinib in treating advanced NSCLC patients with acquired T790M mutation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom